Vanda Pharmaceuticals (VNDA) Shares are Up 25.76%

Vanda Pharmaceuticals (VNDA) : Traders are bullish on Vanda Pharmaceuticals (VNDA) as it has outperformed the S&P 500 by a wide margin of 34.76% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 26.59%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 25.76% in the last 1 week, and is up 34.47% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.

For the current week, the company shares have a recommendation consensus of Buy. The stock has recorded a twenty day Moving Average of 24% and the fifty day Moving Average is 31.1%. Vanda Pharmaceuticals, Inc. is up 44.49% in the last three month period. Year-to-Date the stock performance stands at 64.66%.

Vanda Pharmaceuticals (VNDA) stock is expected to deviate a maximum of $2.65 from the average target price of $17 for the short term period. 3 Street Experts have initiated coverage on the stock with the most promising target being $20 and the most muted being $15.


Vanda Pharmaceuticals (NASDAQ:VNDA): stock turned positive on Friday. Though the stock opened at $14.5, the bulls momentum made the stock top out at $15.38 level for the day. The stock recorded a low of $14.18 and closed the trading day at $15.33, in the green by 8.19%. The total traded volume for the day was 2,668,441. The stock had closed at $14.17 in the previous days trading.

Vanda Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products for the treatment of central nervous system (CNS) disorders. The Companys product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051. HETLIOZ (tasimelteon) is a product for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) for which a New Drug Application (NDA) was approved by the United States Food and Drug Administration (FDA). Fanapt (iloperidone) is a product for the treatment of schizophrenia. Tradipitant (VLY-686) is a small molecule neurokinin-1 receptor (NK-1R) antagonist, which is under clinical development for the treatment of chronic pruritus in atopic dermatitis. Trichostatin A is a small molecule histone deacetylase (HDAC) inhibitor. AQW051 is a Phase II alpha-7 nicotinic acetylcholine receptor partial agonist.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.